It does not yet hold a marketing authorisation from the MHRA, and there is no approved Summary of Product Characteristics (SmPC)
The drugs cost-effectiveness becomes particularly evident among individuals with cardiovascular disease
Approximately 15-20% of users experience significant changes in bowel habits
TRIUMPH restatrutide program, design and schedule : rationale and design of Phase 3 retatrutide trials for obesity, OSA and osteoarthritis
If your vial sits at room temperature for several hours, some potency loss occurs
Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data
